Analyzing Tonix Pharmaceuticals (TNXP) and ContraVir Pharmaceuticals (CTRV)
Tonix Pharmaceuticals (NASDAQ: TNXP) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.
This is a breakdown of current recommendations for Tonix Pharmaceuticals and ContraVir Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
13.5% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 50.5% of ContraVir Pharmaceuticals shares are held by institutional investors. 4.1% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of ContraVir Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Tonix Pharmaceuticals and ContraVir Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tonix Pharmaceuticals||N/A||N/A||-$21.12 million||($2.90)||-0.36|
This table compares Tonix Pharmaceuticals and ContraVir Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Tonix Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.
ContraVir Pharmaceuticals beats Tonix Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.